Plain-English translation of NCT05415267 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing the best time to give a COVID-19 booster vaccine to people who are about to start taking strong immunosuppressive medications (medicines that calm down the immune system). Researchers want to know whether it's better to boost immunity right away, before starting the new treatment, or to wait a few months until after the immunosuppressive therapy has begun.
Current medical guidelines for vaccinating people on immunosuppressive therapy are based on limited evidence and sometimes contradict each other. This study will provide clear, practical answers about whether this medication works better when given before or after immunosuppression begins—helping doctors make better decisions for their patients.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of four groups that receive either a COVID-19 booster vaccine or a tetanus booster at the start of the study, with the other vaccine given 24 weeks later. You'll have visits at key timepoints to check how well your immune system is responding to the vaccines. The study follows you for about 6 months while you begin your new immunosuppressive therapy.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
Australia